

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): November 10, 2022**

**ATRECA, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or Other Jurisdiction of Incorporation)

**001-38935**  
(Commission File Number)

**27-3723255**  
(I.R.S. Employer Identification No.)

**835 Industrial Rd., Suite 400  
San Carlos, California 94070**  
(Address of Principal Executive Offices) (Zip Code)

**(650) 595-2595**  
(Registrant's telephone number, including area code)

**Not Applicable**  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Class A Common Stock, \$0.0001 par value per share	BCEL	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 2.02. Results of Operations and Financial Condition.**

On November 10, 2022, Atreca, Inc. (the “**Company**”) issued a press release reporting its financial results for the quarter ended September 30, 2022 and recent corporate developments. A copy of such press release is furnished hereto as Exhibit 99.1.

The information contained in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended, nor shall it be deemed incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, except as expressly set forth by reference in such a filing.

**Item 9.01. Financial Statements and Exhibits.****(d) Exhibits**

<u>Exhibit Number</u>	<u>Exhibit Description</u>
<a href="#">99.1</a>	<a href="#">Press Release titled "Atreca Reports Third Quarter 2022 Financial Results and Provides Pipeline Update," dated November 10, 2022, furnished herewith</a>
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Atreca, Inc.**

Date: November 10, 2022

By: /s/ Herbert Cross  
Herbert Cross  
Chief Financial Officer

## Atreca Reports Third Quarter 2022 Financial Results and Provides Pipeline Update

SAN CARLOS, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- SAN CARLOS, Calif., November 10, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the third quarter ended September 30, 2022 and provided an overview of recent developments.

"The third quarter was a productive period, as we continue to enroll patients in the Phase 1b trial of ATRC-101," said John Orwin, Chief Executive Officer of Atreca. "We remain encouraged by the association we see between clinical activity and target expression, the durability of the clinical activity observed and the tolerability demonstrated in the study. We are making progress toward accelerating enrollment and are now planning to present data in early 2023, once we've treated enough participants to provide a meaningful update."

"An NHP toxicity study to evaluate ATRC-301, an ADC candidate in our anti-EphA2 program, revealed safety signals, including bleeding, and as a result, we are discontinuing the development of ATRC-301; however, we continue to evaluate our anti-EphA2 antibodies in multiple weaponized formats," said Stephen Gould, Ph.D., Chief Scientific Officer of Atreca. "While this will delay the timing of our next IND in oncology, our preclinical pipeline is otherwise progressing well, and in early 2023 we expect to provide updates on both an ADC targeting a novel tumor glycan and a bispecific T-cell engager targeting another RNA-binding protein."

"In addition, the Bill & Melinda Gates Medical Research Institute continues to advance MAM01/ATRC-501, an antibody clinical candidate generated by the Atreca platform that is in development for the prevention of malaria, for which they expect to file an IND early next year," said John Orwin.

### Recent Developments and Highlights

Atreca continued enrolling patients in its ongoing Phase 1b study of ATRC-101 based on ATRC-101 target expression in archival or newly obtained biopsies. To-date, 67 participants have been enrolled across the monotherapy and pembrolizumab combination cohorts of the study. The Company has taken steps to accelerate enrollment in the trial, including initiating additional trial sites and streamlining enrollment criteria. Atreca now expects to present updated monotherapy and combination data from the trial in the first quarter of 2023.

An non-human primate (NHP) toxicity study to evaluate ATRC-301, an antibody drug conjugate (ADC) candidate in our anti-EphA2 program, revealed safety signals, including bleeding, and as a result, Atreca is discontinuing the development of ATRC-301. The Company continues to evaluate its anti-EphA2 antibodies in multiple weaponized formats and advance its other lead-stage oncology programs, including APN-497444, an ADC against a novel tumor glycan target, and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. Atreca is now targeting one additional Investigational New Drug (IND) application per year in oncology beginning in 2024.

A IND for MAM01/ATRC-501, an Atreca-discovered antibody clinical candidate licensed to the Bill & Melinda Gates Medical Research Institute ("Gates MRI") for the prevention of malaria, is expected to be filed by Gates MRI in the first quarter of 2023, and they expect to commence clinical development by the second half of 2023. Atreca retains commercial rights in the U.S., Europe and parts of Asia, and potential product development opportunities in those regions include prevention of malaria for those traveling to malaria endemic regions.

In October 2022, Atreca announced the presentation of two posters at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, a trial-in-progress update on the Phase 1b clinical study of ATRC-101, and a poster on the discovery and preclinical development of its novel EphA2-targeted antibodies. Poster sessions began today, November 10<sup>th</sup>, at 9 a.m. ET.

### Third Quarter 2022 Financial Results

- As of September 30, 2022, cash and cash equivalents and investments totaled \$85.7 million.
- Research and development expenses for the quarter ended September 30, 2022, were \$16.0 million, including non-cash share-based compensation expense of \$1.9 million.
- General and administrative expenses for the three months ended September 30, 2022, were \$7.2 million, including non-cash share-based compensation expense of \$2.0 million.
- Atreca reported a net loss of \$23.1 million, or basic and diluted net loss per share attributable to common stockholders of \$0.60, for the three months ended September 30, 2022.

### About Atreca, Inc.

Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies

provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101, our pipeline of lead-stage oncology programs, and MAM01/ATRC-501, a clinical candidate licensed to the Bill & Melinda Gates Medical Research Institute for the prevention of malaria. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit [www.atreca.com](http://www.atreca.com).

## Forward-Looking Statements

This release contains forward-looking statements regarding our strategy and future plans, including statements regarding enrollment of patients in our Phase 1b clinical trial of ATRC-101, the development of ATRC-101 and our clinical and regulatory plans, and the timing thereof, data read-outs and the timing thereof, including the reporting of updated data from the monotherapy and pembrolizumab combination arms of our Phase 1b clinical trial of ATRC-101, our evaluation of anti-EphA2 antibodies in multiple weaponized formats and advancement of other lead-stage oncology programs, including APN-497444 and APN-346958, the expected timing of INDs, including delays thereof and plans to submit one additional IND per year in oncology beginning in 2024, advancement of MAM01/ATRC-501 by Gates MRI, including plans to commence clinical development by the second half of 2023. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as “continue,” “progress,” “accelerate,” “will,” “expect,” “advance,” “target,” and similar words, although some forward-looking statements are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, clinical trials, regulatory submissions, and other matters that are described in our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) and available on the SEC's website at [www.sec.gov](http://www.sec.gov), including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.

**Atreca, Inc.**  
**Condensed Consolidated Balance Sheets**  
*(in thousands, except share and per share data)*

	<b>September 30, 2022</b>	<b>December 31, 2021</b>
	<b>(unaudited)</b>	
<b>ASSETS</b>		
Current Assets		
Cash and cash equivalents	\$ 20,903	\$ 94,746
Investments	64,822	22,287
Prepaid expenses and other current assets	7,050	5,337
Total current assets	92,775	122,370
Property and equipment, net	39,670	43,015
Operating lease right-of-use assets	36,481	-
Long-term investments	-	31,042
Deposits and other	3,149	3,630
Total assets	\$ 172,075	\$ 200,057
<b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>		
Current Liabilities		
Accounts payable	\$ 1,698	\$ 3,352
Accrued expenses	9,399	11,555
Current portion of operating lease liabilities	3,434	-

Other current liabilities	39	1,992
Total current liabilities	14,570	16,899
Deferred rent	-	28,229
Operating lease liabilities, net of current portion	61,252	-
Total liabilities	75,822	45,128
Stockholders' equity		
Common stock	4	4
Additional paid-in capital	532,409	514,794
Accumulated other comprehensive income (loss)	(581)	(102)
Accumulated deficit	(435,579)	(359,767)
Total stockholders' equity	96,253	154,929
Total liabilities and stockholders' equity	\$ 172,075	\$ 200,057

**Atreca, Inc.**  
**Condensed Consolidated Statements of Operations**  
*(in thousands, except share and per share data)*  
*(unaudited)*

(\$ amounts in 000's, except per share amounts)

	<b>Three Months Ended</b>		<b>Nine Months Ended</b>	
	<b>September 30,</b>		<b>September 30,</b>	
	<b>2022</b>	<b>2021</b>	<b>2022</b>	<b>2021</b>
Expenses				
Research and development	\$ 16,045	\$ 18,721	\$ 53,062	\$ 56,145
General and administrative	7,247	8,796	23,930	24,648
Total expenses	23,292	27,517	76,992	80,793
Interest and other income (expense)				
Other income	-	158	750	851
Interest income	233	36	430	183
Interest expense	-	(1)	-	(3)
Loss on disposal of property and equipment	-	(34)	-	(45)
Loss before Income tax expense	(23,059)	(27,358)	(75,812)	(79,807)
Income tax expense	-	-	-	(1)
Net loss	<u>\$ (23,059)</u>	<u>\$ (27,358)</u>	<u>\$ (75,812)</u>	<u>\$ (79,808)</u>
Net loss per share, basic and diluted	<u>\$ (0.60)</u>	<u>\$ (0.74)</u>	<u>\$ (1.97)</u>	<u>\$ (2.16)</u>
Weighted-average shares used in computing net loss per share, basic and diluted	<u>38,720,575</u>	<u>36,918,255</u>	<u>38,434,327</u>	<u>36,884,665</u>

**Contacts**

Atreca, Inc.  
Herb Cross

Chief Financial Officer  
info@atreca.com

Investors:  
Alex Gray, 650-779-9251  
agray@atreca.com

Media:  
Julia Fuller, 858-692-2001  
julia@fordhutmanmedia.com  
Source: Atreca, Inc.